WC
Boston Scientific Pipeline
| Drug | Indication | Phase |
|---|---|---|
| WATCHMAN FLX™ Left Atrial Appendage Closure Device | Atrial Fibrillation Stroke Prevention | Approved/Commercial |
| FARAPULSE™ Pulsed Field Ablation System | Paroxysmal Atrial Fibrillation | Approved/Commercial |
| AGENT™ Drug-Coated Balloon | Coronary In-Stent Restenosis | Approved/Commercial |
| ROTAPRO™ Rotational Atherectomy System | Coronary Artery Calcification | Approved/Commercial |
| ACURATE neo2™ Aortic Valve System | Aortic Stenosis | Approved/Commercial |
| LUX-Dx™ Insertable Cardiac Monitor | Cardiac Arrhythmia Detection | Approved/Commercial |
| Vercise™ Genus Deep Brain Stimulation System | Parkinson's Disease, Essential Tremor, Dystonia | Approved/Commercial |
| WaveWriter™ Spinal Cord Stimulator System | Chronic Pain | Approved/Commercial |
Leadership Team at Boston Scientific
MF
Michael F. Mahoney
Chairman and Chief Executive Officer
DJ
Daniel J. Brennan
Executive Vice President and Chief Financial Officer
JM
Joseph M. Fitzgerald
Executive Vice President and President, MedSurg
MC
Michael C. Jones
Executive Vice President and President, Cardiology
DA
David A. Pierce
Executive Vice President and President, Neuromodulation
AC
Arthur C. Butcher
Executive Vice President and Chief Operating Officer
SE
Susan E. Morano
Executive Vice President and Chief Human Resources Officer
EJ
Edward J. Mackey
Executive Vice President and Chief Legal Officer
DW
David W. McFaul
Executive Vice President and Chief Technology Officer
MS
Meghan Scanlon
Executive Vice President and President, Urology